Gilead Sciences (GILD +1.4%) keeps the positive momentum churning after announcing it landed EU...

|About: Gilead Sciences, Inc. (GILD)|By:, SA News Editor

Gilead Sciences (GILD +1.4%) keeps the positive momentum churning after announcing it landed EU approval for its Eviplera treatment for HIV-1 infection - clearing the way for the commercial development of the drug in all 27 member countries. Shares of GILD now stand just a hair below where they traded just prior to the announcement of its blockbuster purchase of Pharmasset (VRUS +0.1%).